ABGSC acted as joint global coordinator and joint bookrunner in connection with the NOK 232m private placement in Nordic Nanovector ASA

Nordic Nanovector ASA (”Nordic Nanovector”) announced on Wednesday 23 September the successful completion of a private placement of 13,228,670 new shares, equivalent to ~20% of the share capital pre issue. The shares were priced at NOK 17.50 per share, raising gross proceeds of NOK 232m.
The net proceeds from the Private Placement will be used to:
– Further progress the pivotal PARADIGME Phase 2b trial with Betalutin® in patients with 3rd-line relapsed/refractory Follicular Lymphoma (3L R/R FL).
– Conduct Pharmacokinetics (PK) studies and execute CMC activities required for the planned BLA (Biological License Application) filing.
– Initiate the preparatory activities for the confirmatory phase 3 trial.
– General corporate purposes.
The Private Placement, which was oversubscribed, attracted strong interest from both existing shareholders and new institutional investors, Norwegian as well as international.